Kalaris Therapeutics annual return on equity
2020
2021
2022
2023
Kalaris Therapeutics Return on Equity (ROE) Growth & History (KLRS)
Kalaris Therapeutics's return on equity was −212.16% for fiscal 2023.
View full Kalaris Therapeutics company overviewKalaris Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −212.16% | −137.14 pp |
| 2022 | 2022-12-31 | −75.02% | −15.55 pp |
| 2021 | 2021-12-31 | −59.47% | −13.19 pp |
| 2020 | 2020-12-31 | −46.28% | — |
Kalaris Therapeutics quarterly return on equity
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −18.24% | +1.16 pp |
| Q1 2026 | 2026-03-31 | −14.73% | — |
| Q4 2025 | 2025-12-31 | −16.57% | — |
| Q3 2025 | 2025-09-30 | −25.05% | — |
| Q2 2025 | 2025-06-30 | −19.40% | — |
| Q4 2023 | 2023-12-31 | −79.43% | −63.46 pp |
| Q3 2023 | 2023-09-30 | −20.86% | −0.41 pp |
| Q2 2023 | 2023-06-30 | −21.42% | +4.10 pp |
| Q1 2023 | 2023-03-31 | −19.70% | +1.34 pp |
| Q4 2022 | 2022-12-31 | −15.97% | +7.56 pp |
| Q3 2022 | 2022-09-30 | −20.45% | −4.48 pp |
| Q2 2022 | 2022-06-30 | −25.52% | −13.64 pp |
| Q1 2022 | 2022-03-31 | −21.04% | −11.99 pp |
| Q4 2021 | 2021-12-31 | −23.53% | −16.59 pp |
| Q3 2021 | 2021-09-30 | −15.97% | −0.37 pp |
| Q2 2021 | 2021-06-30 | −11.88% | — |
| Q1 2021 | 2021-03-31 | −9.05% | — |
| Q4 2020 | 2020-12-31 | −6.93% | — |
| Q3 2020 | 2020-09-30 | −15.61% | — |
Kalaris Therapeutics return on equity trends
Between the periods ended 2020-12-31 and 2023-12-31, Kalaris Therapeutics's return on equity decreased from −46.28% to −212.16%, a change of −165.88 percentage points. The latest reported quarter, Q2 2026, shows −18.24%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kalaris Therapeutics source filings ↗